Erasca (ERAS) Non-Current Assets (2020 - 2026)
Erasca (ERAS) posted Non-Current Assets of $207.4 million for Q1 2026, up 88.74% on a QoQ basis from $109.9 million in Q4 2025, and up 32.45% year-over-year from $156.6 million in Q1 2025.
Erasca (ERAS) Non-Current Assets (2020 - 2026) Analysis & Trends
Erasca's Non-Current Assets history runs 7 years deep, the most recent figure standing at $207.4 million for Q1 2026.
- Quarterly Non-Current Assets rose 32.45% year-over-year to $207.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $572.6 million (down 12.83% YoY) and the FY2025 annual result came in at $109.9 million, down 43.26% from the prior year.
- Non-Current Assets was $207.4 million for Q1 2026 at Erasca, up from $109.9 million in the prior quarter.
- Across five years, Non-Current Assets topped out at $207.4 million in Q1 2026 and bottomed at $63.4 million in Q1 2024.
- A 5-year average of $114.9 million and a median of $109.9 million in 2025 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets soared 384.28% — and 2025, when it tumbled 43.26%.
- Erasca's Non-Current Assets stood at $70.4 million in 2022, then grew by 5.98% to $74.6 million in 2023, then surged by 159.62% to $193.7 million in 2024, then tumbled by 43.26% to $109.9 million in 2025, then soared by 88.74% to $207.4 million in 2026.
- Business Quant data shows ERAS's Non-Current Assets at $207.4 million in Q1 2026, $109.9 million in Q4 2025, and $120.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 21.65 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 5.83 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.95 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 3.95 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.75 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 22.66 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 289.41 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.96 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 285.82 Mn |
| 10 | Erasca | 5.89 Bn | 5.89 Bn | - | 207.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 207.45 Mn |
| Dec 31, 2025 | 109.92 Mn |
| Sep 30, 2025 | 120.48 Mn |
| Jun 30, 2025 | 134.73 Mn |
| Mar 31, 2025 | 156.63 Mn |
| Dec 31, 2024 | 193.73 Mn |
| Sep 30, 2024 | 198.72 Mn |
| Jun 30, 2024 | 107.74 Mn |
| Mar 31, 2024 | 63.40 Mn |
| Dec 31, 2023 | 74.62 Mn |
| Sep 30, 2023 | 113.44 Mn |
| Jun 30, 2023 | 116.81 Mn |
| Mar 31, 2023 | 69.66 Mn |
| Dec 31, 2022 | 70.41 Mn |
| Sep 30, 2022 | 80.68 Mn |
| Jun 30, 2022 | 63.40 Mn |
| Mar 31, 2022 | 72.10 Mn |
| Dec 31, 2021 | 81.40 Mn |
| Sep 30, 2021 | 29.64 Mn |
| Jun 30, 2021 | 13.09 Mn |